Yan Leyfman: Using routine blood tests to predict immunotherapy response across multiple cancers
Yan Leyfman, Co-founder and executive director of MedNews Week, shared on LinkedIn:
“Honored to contribute to this groundbreaking work with the incredible Drs. Fitzgerald, Diego Chowell, and Thomas Marron.
Memorial Sloan Kettering Cancer Center and Icahn School of Medicine at Mount Sinai unveil SCORPIO — an innovative AI tool using routine blood tests to predict immunotherapy response across multiple cancers. Changing the game in cancer care! ”
Authors: Seong-Keun Yoo, Conall W. Fitzgerald, Byuri Angela Cho, Bailey G. Fitzgerald, Catherine Han, Elizabeth S. Koh, Abhinav Pandey, Hannah Sfreddo, Fionnuala Crowley, Michelle Rudshteyn Korostin, Neha Debnath, Yan Leyfman, Cristina Valero, Mark Lee, Joris L. Vos, Andrew Sangho Lee, Karena Zhao, Stanley Lam, Ezekiel Olumuyide, Fengshen Kuo, Eric A. Wilson, Pauline Hamon, Clotilde Hennequin, Miriam Saffern, Lynda Vuong, A. Ari Hakimi, Brian Brown, Miriam Merad, Sacha Gnjatic, Nina Bhardwaj, Matthew D. Galsky, Eric E. Schadt, Robert M. Samstein, Thomas U. Marron, Mithat Gönen, Luc G. T. Morris.
Yan Leyfman MD, is the Co-founder and executive director of MedNews Week. He is also the Medical correspondent at OncLive. He is the Executive Committee Member at Music Beats Cancer.
He is a Clinical Researcher at Icahn School of Medicine at Mount Sinai. His research interests include oncology, Immunooncology, Cellular Therapy, and Immunotherapy.
More posts featuring Yan Leyfman.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023